TZP is a dual GLP-1 RA and gastric inhibitory polypeptide receptor agonist (GIP RA) (15), which can stimulate insulin secretion by dual activation of glucagon like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) in the presence of hyperglycemic state (16) and improve glycemic control in T2DM. Here, GCG is linked to type 2 diabetes mellitus.